Digital Repository

Hepatocellular carcinoma in Sri Lanka: Where do we stand?

Show simple item record

dc.contributor.author Siriwardana, R.C.
dc.contributor.author Liyanage, C.A.H.L.
dc.contributor.author Jayatunge, D.S.P.
dc.contributor.author Dassanayaka, A.
dc.contributor.author Gunetileke, M.G.
dc.contributor.author Niriella, M.A.
dc.contributor.author Sirigampola, C.
dc.contributor.author Upasena, A.
dc.contributor.author de Silva, H.J.
dc.date.accessioned 2023-06-08T07:40:48Z
dc.date.available 2023-06-08T07:40:48Z
dc.date.issued 2013
dc.identifier.citation Sri Lanka Medical Association, 126th Anniversary Scientific Medical Congress. 2013; 58 Supplement 1: 29 en_US
dc.identifier.issn 0009-0895
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/26366
dc.description Oral Presentation Abstract (OP 45), 126th Anniversary Scientific Medical Congress, Sri Lanka Medical Association, 10th-13th July 2013 Colombo, Sri Lanka en_US
dc.description.abstract INTRODUCTION AND OBJECTIVES:Hepato-cellular carcinoma (HCC) is the sixth commonest cancer worldwide. We studied 105 consecutive patients with HCC in a single tertiary care centre. METHODS: North Colombo Liver Unit maintains a prospective database of HCC since September 2011. There were 105 entries by February 2013. Decision on the best form of treatment was taken at a multidisciplinary meeting. RESULTS: The median age at presentation was 63 years (range 12-79). Patients were predominantly male 93 (87%). Alcohol consumption above the safe limit was reported in 47 (45%). Hepatitis B surface antigen or C antibody was not detected in any of the patients. Background liver cirrhosis was evident in 59 (79%). Forty two (46%) patients had single nodular tumours while in 20 (21%) it was diffusely infiltrating. Portal vein invasion was seen in 22 (20 %). Median alpha-feto protein (AFP) level was 57.25 mg/ml (1.16- 94120 ng/ml; n=72). Twenty four (33%) patients had AFP level > 400u/l. Surgery was performed in 20 (19%), liver transplant in 2 (1.9%), radio frequency ablation or alcohol ablation in 8 (7.6%), trans arterial chemo embolization (TACE) in 44 (41.9%) and sorafmib was prescribed in four patients. Overall mean survival was 15 months. In the ‘no treatment’ group, mean survival was 4 months. Surgery group had a mean survival of 20 months. CONCLUSION: Hepatitis B is not a risk factor for HCC in Sri Lankans. Median survival without treatment is 4 months. en_US
dc.language.iso en en_US
dc.publisher Sri Lanka Medical Association en_US
dc.subject Hepatocellular carcinoma en_US
dc.title Hepatocellular carcinoma in Sri Lanka: Where do we stand? en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference Papers
    Papers presented at local and international conferences by the Staff of the Faculty of Medicine

Show simple item record

Search Digital Repository


Browse

My Account